Physician profile
Michael Kuo
NPI 1275881054
$2,697.72
in general payments reported to CMS, 2019-2025
32 companies · $160 in 2025
The $160 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $520 · 2021: $395 · 2022: $262 · 2023: $301 · 2024: $243 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $644.48 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $239.25 | 2019-2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $199.03 | 2019-2021 | |
| Abbott Laboratories | $189.35 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $160.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $132.78 | 2021-2022 | |
| Pfizer INC. | $113.80 | 2019-2023 | |
| Amarin Pharma, INC. | $98.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $86.15 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $80.71 | 2019-2024 | |
| Dynavax Technologies Corporation | $72.36 | 2019-2024 | Heplisav-B |
| Dexcom, INC. | $56.63 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.99 | 2019-2021 | |
| Glaxosmithkline, LLC. | $54.88 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $53.18 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $47.28 | 2023-2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $43.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $43.01 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $40.73 | 2023-2025 | Ingrezza |
| Horizon Therapeutics Plc | $36.77 | 2019-2020 | |
| Abbvie INC. | $28.67 | 2021 | |
| Boston Scientific Corporation | $27.86 | 2023 | |
| Hikma Pharmaceuticals USA | $27.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.24 | 2019 | |
| Astellas Pharma US INC | $26.13 | 2019-2020 | |
| Inspire Medical Systems, INC. | $24.62 | 2024 | Inspire |
| Eisai INC. | $16.91 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $16.40 | 2023 | Prehevbrio |
| Daiichi Sankyo INC. | $15.08 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.43 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.74 | 2019 | |
| Merz Pharmaceuticals, LLC | $13.48 | 2024 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.